Biomunex Pharmaceuticals is Drug Discovery in France that focus on drug-like properties business. Founded in 2014. They cover business area such as developer, immunotherapy, therapeutic, immuno-oncology, drug candidate, high anti-tumor potential, superior manufacturability, optimal drug-like property, biotechnology company, any pair, monospecific monoclonal, building, block.
2014
( 10 years old in 2024 )
Drug-like Properties
-
14 avenue d'Eylau
75116 Paris
France
Private
developerimmunotherapytherapeuticimmuno-oncologydrug candidatehigh anti-tumor potentialsuperior manufacturabilityoptimal drug-like propertybiotechnology companyany pairmonospecific monoclonalbuildingblock
* We use standard office opening hours in near Biomunex Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Biomunex Pharmaceuticals is Drug Discovery business from France that founded in 2014 (10 years old in 2024), Biomunex Pharmaceuticals business is focusing on Drug-like Properties.
Biomunex Pharmaceuticals headquarter office and corporate office address is located in 14 avenue d'Eylau 75116 Paris France.
Biomunex Pharmaceuticals was founded in France.
In 2024, Biomunex Pharmaceuticals is currently focus on drug-like properties sector.
Above is snippet of Google Trends for "drug-like properties" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Biomunex Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
